Based on the observed CIRs (table 3) and insights on the importance of past intravitreal anti-VEGF exposures on risk of PDR (online supplemental figure 2), review under mydriasis for NPDR eyes with DMO undergoing anti-VEGF treatment should not be delayed more than the established recommendations of point of care DR screening (ie, every 12 months for mild-NPDR, 6 months for moderate-NPDR and 3–4 months for severe-NPDR) and account for age of the participant on a case-by-case basis. Here, VEGFA is linked to Mydriasis.